

In the Specification

Please replace the paragraph at page 103, lines 16 through 22 with the following paragraph:

Q  
1

For the renal cell carcinoma cell model, 2 million 786-O cells were injected subcutaneously into 7- to 9-week-old male athymic nude mice. The tumors were allowed to grow to either about 100 mm<sup>3</sup> or about 700 mm<sup>3</sup>. Each group contained 6 mice. Canstatin in sterile PBS was injected I.P. daily at a concentration of 10 mg/kg for 10 days. The control group received the same volume of PBS. The results are shown in Figs. 17C (100 mm<sup>3</sup> tumors) and 17D (700 mm<sup>3</sup> tumors). In both groups, the Canstatin-treated (■) tumors actually shrank relative to the controls (□).

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (page i).

In the Claims

Please cancel Claims 5-7.

Please amend Claims 1-4 as follows. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (page ii).

- 2  
Sub C1
1. (Amended) A composition comprising an isolated non-Goodpasture fragment of  $\alpha 3(\text{IV})$  NC1 domain, having one or both of the following characteristics selected from the group consisting of:
    - (a) the ability to bind  $\alpha_v\beta_3$  integrin; and
    - (b) the ability to inhibit proliferation of endothelial cells; anda pharmaceutically-acceptable carrier.